Compared to traditional chemotherapy, first-generation EGFR-TKIs can effectively improve the objective response rate (ORR) and progression-free survival (PFS) of NSCLC patients with EGFR mutations, and are also associated with fewer adverse reactions. This evidence concerns the gene EGFR and non-small cell lung carcinoma.